biotech / news / / MIT Technology Review
Moderna, the covid-19 shot maker, has had plans for next-generation mRNA vaccines against flus and emerging pathogens dashed by vaccine skeptics in the federal.
Moderna rebranded its cancer vaccine as 'individualized neoantigen therapy' in 2023 after partnering with Merck.
KEY POINTS
- The rebranding aims to distance the treatment from vaccine skepticism among US officials and regulators.
- Federal agencies under Robert F. Kennedy Jr. canceled Moderna's $776 million bird flu vaccine contract.
- Moderna and Merck's mRNA cancer shot halved recurrence risk in deadly skin cancer patients after surgery.
- BioNTech has also shifted its language from 'neoantigen vaccine' to 'mRNA cancer immunotherapies' recently.
COMPANIES
Summarized by Newsio from MIT Technology Review. How we summarize →